Abilify (generic name: Aripiprazole; brand names include: Arizol / Arlemide / Brisking / Ilimit / Irazem) is an atypical antipsychotic.
Abilify is indicated for:
Use as an add-on treatment to antidepressants for major depressive disorder in adults.
Treatment of manic and mixed episodes associated with bipolar I disorder in adults and in pediatric patients 10 to 17 years of age.
Treatment of schizophrenia in adults and in adolescents 13 to 17 years of age.
Abilify is the first medication approved by the FDA to help improve symptoms of depression in adults when added to an antidepressant. If you have unresolved symptoms of depression, Abilify may help you get additional symptom relief. In clinical trials with add-on Abilify, some patients experienced a significant improvement in symptoms of depression as early as 1 to 2 weeks.
Abilify has been shown to help improve a range of symptoms associated with schizophrenia, which may include:
hearing voices;
thinking unclearly;
having uncomfortable or disturbing thoughts;
feeling confused;
lacking interest in the things you previously enjoyed.
Abilify is proven to help manage symptoms of manic episodes associated with bipolar disorder I and to reduce the risk of manic relapse.
On average, in clinical studies, Abilify did not elevate prolactin, cholesterol or fasting glucose levels.
